Hong Kong's New Competition Law Could Have Impact On Drug Firms Around The World
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Hong Kong's Legislative Council has begun reviewing a new competition bill that, depending on the contours of the law that is ultimately approved, could have a significant impact on the healthcare sector and life science-based enterprises, according to two lawyers who have closely studied the bill
You may also be interested in...
Novartis Tagged With Anti-monopoly Conditions In China For Alcon Acquisition
HONG KONG - China's growing assertiveness in commercial matters is becoming evident in its influence on merger and acquisitions matters and its willingness to impose conditions under its two-year-old anti-monopoly law
China Orders Pfizer And Wyeth To Divest Certain Operations As Condition To Merger Approval
BEIJING - China's Ministry of Commerce has ordered Pfizer and Wyeth to divest themselves of certain business operations here in order to gain government approval for their $68-billion merger
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).